These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 22588782)

  • 21. Investigational chemotherapy of neuroblastoma.
    Helson L
    J Fla Med Assoc; 1979 Mar; 66(3):284-7. PubMed ID: 422952
    [No Abstract]   [Full Text] [Related]  

  • 22. [Diagnostic and therapeutic possibilities of meta-iodobenzylguanidine in neuroblastoma].
    Guerra P
    Pediatr Med Chir; 1990; 12(6):663-8. PubMed ID: 2093889
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Therapeutic results in neuroblastoma].
    Madon E; Baroncelli PG; Sacerdote A; Cordero di Montezemolo L; Pastore G
    Minerva Pediatr; 1976 Nov; 28(36):2187-94. PubMed ID: 995100
    [No Abstract]   [Full Text] [Related]  

  • 24. In brief: Dinutuximab (Unituxin) for high-risk neuroblastoma.
    Med Lett Drugs Ther; 2016 Mar; 58(1491):e48. PubMed ID: 27027692
    [No Abstract]   [Full Text] [Related]  

  • 25. GD2-targeted immunotherapy and potential value of circulating microRNAs in neuroblastoma.
    Gholamin S; Mirzaei H; Razavi SM; Hassanian SM; Saadatpour L; Masoudifar A; ShahidSales S; Avan A
    J Cell Physiol; 2018 Feb; 233(2):866-879. PubMed ID: 28145567
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Investigational drugs in phase II clinical trials for the treatment of neuroblastoma.
    Amoroso L; Haupt R; Garaventa A; Ponzoni M
    Expert Opin Investig Drugs; 2017 Nov; 26(11):1281-1293. PubMed ID: 28906153
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cytolytic effects of bromoacetylcholine on neuroblastoma in vitro.
    Chiou CY
    J Pharm Sci; 1975 Mar; 64(3):469-70. PubMed ID: 1171213
    [No Abstract]   [Full Text] [Related]  

  • 28. Exploitation of the Apoptosis-Primed State of MYCN-Amplified Neuroblastoma to Develop a Potent and Specific Targeted Therapy Combination.
    Ham J; Costa C; Sano R; Lochmann TL; Sennott EM; Patel NU; Dastur A; Gomez-Caraballo M; Krytska K; Hata AN; Floros KV; Hughes MT; Jakubik CT; Heisey DA; Ferrell JT; Bristol ML; March RJ; Yates C; Hicks MA; Nakajima W; Gowda M; Windle BE; Dozmorov MG; Garnett MJ; McDermott U; Harada H; Taylor SM; Morgan IM; Benes CH; Engelman JA; Mossé YP; Faber AC
    Cancer Cell; 2016 Feb; 29(2):159-72. PubMed ID: 26859456
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Correlation of cellular tritiated thymidine incorporation with soft agar clonogenicity in chemosensitivity testing of human neuroblastoma cells.
    Johnson GE; Glaubiger DL
    Cancer Treat Rep; 1983 Feb; 67(2):163-8. PubMed ID: 6825124
    [No Abstract]   [Full Text] [Related]  

  • 30. Phase II trial of amsacrine in children with advanced metastatic neuroblastoma.
    De Bernardi B; Pastore G; Garaventa A; Calculli G; Carli M; Ceci A; di Montezemolo LC; Pianca C; Romano C; Russo A
    Cancer Treat Rep; 1984; 68(7-8):1051-2. PubMed ID: 6547640
    [No Abstract]   [Full Text] [Related]  

  • 31. Emerging drugs for neuroblastoma.
    Castel V; Segura V; Berlanga P
    Expert Opin Emerg Drugs; 2013 Jun; 18(2):155-71. PubMed ID: 23692586
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacokinetics and pharmacogenetics of 13-cis retinoic acid in Indian high-risk neuroblastoma patients.
    Gota V; Chinnaswamy G; Vora T; Rath S; Yadav A; Gurjar M; Veal G; Kurkure P
    Cancer Chemother Pharmacol; 2016 Oct; 78(4):763-8. PubMed ID: 27541143
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Chemotherapy of neuroblastoma.
    Helson L
    Clin Bull; 1975; 5(2):47-50. PubMed ID: 1227732
    [No Abstract]   [Full Text] [Related]  

  • 34. Altered expression of the MYCN oncogene modulates MRP gene expression and response to cytotoxic drugs in neuroblastoma cells.
    Haber M; Bordow SB; Gilbert J; Madafiglio J; Kavallaris M; Marshall GM; Mechetner EB; Fruehauf JP; Tee L; Cohn SL; Salwen H; Schmidt ML; Norris MD
    Oncogene; 1999 Apr; 18(17):2777-82. PubMed ID: 10348353
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Response to rituximab in a child with neuroblastoma and opsoclonus-myoclonus.
    Bell J; Moran C; Blatt J
    Pediatr Blood Cancer; 2008 Feb; 50(2):370-1. PubMed ID: 16652344
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Case report: value of gene expression profiling in the diagnosis of atypical neuroblastoma.
    Harttrampf AC; Chen Q; Jüttner E; Geiger J; Vansant G; Khan J; Kontny U
    BMC Res Notes; 2017 Aug; 10(1):413. PubMed ID: 28818093
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ukrain treatment in a patient with stage IV neuroblastoma. A case report.
    Aschhoff B
    Drugs Exp Clin Res; 1998; 24(5-6):243-5. PubMed ID: 10190082
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Synthesis of carrier-free 131I-meta-iodobenzyl-guanidine by novel routes to enhance therapeutic efficiency in neuroblastoma.
    Gaze MN; Mairs RJ; Vaidyanathan G; Zalutsky MR
    Prog Clin Biol Res; 1994; 385():347-53. PubMed ID: 7972229
    [No Abstract]   [Full Text] [Related]  

  • 39. Congenital neuroblastoma with multiple subcutaneous noduls.
    Ansari S; Hossini AA; Solimani SM
    Pediatr Hematol Oncol; 2007; 24(1):85-6. PubMed ID: 17130119
    [No Abstract]   [Full Text] [Related]  

  • 40. Modulation of chemotherapeutic drug resistance in neuroblastoma SK-N-AS cells by the neural apoptosis inhibitory protein and miR-520f.
    Harvey H; Piskareva O; Creevey L; Alcock LC; Buckley PG; O'Sullivan MJ; Segura MF; Gallego S; Stallings RL; Bray IM
    Int J Cancer; 2015 Apr; 136(7):1579-88. PubMed ID: 25137037
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.